NCT04190628 2024-05-21Safety and Tolerability of ABM-1310 in Patients With Advanced Solid TumorsABM Therapeutics CorporationPhase 1 Terminated53 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT02818023 2022-01-03Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced MelanomaUniversity of PittsburghPhase 1 Terminated9 enrolled